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Narrative Abstract: 
Systemic lupus erythematosus (SLE) is a life-threatening multi-system inflammatory condition that 
may affect almost any part of the eye. We provide an update for the practicing ophthalmologist 
comprising a systematic review of the recent literature presented in the context of current 
knowledge of the pathogenesis, diagnosis and treatment of this condition. We review recent 
advances in the understanding of the influence of genetic and environmental factors on the 
development of SLE. Recent changes in the diagnostic criteria for SLE are considered. We assess the 
potential for novel molecular biomarkers to find a clinical application in disease diagnosis and 
stratification and in the development of therapeutic agents. We discuss limited forms of SLE and 
their differentiation from other collagen vascular disorders and review recent evidence underlying 
the use of established and novel therapeutics in this condition, including specific implications 
regarding monitoring for ocular toxicity associated with antimalarials.  
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I. Introduction 
A. Systemic Lupus Erythematosus (SLE) and the Ophthalmologist 
Systemic Lupus Erythematosus (SLE) is a life-threatening multisystem 
autoimmune disease. Around a third of patients may have ocular involvement, 
ranging from relatively mild manifestations to severe, sight-threatening 
disease. The role of ophthalmologists in the care of these patients ranges from 
contributing to the acute care of a patient with severe active disease to the 
longer-term management of complications arising from the disease or related 
to its treatment. 
B. Update on Epidemiology and Global Impact 
1. Worldwide incidence and prevalence 
The incidence and prevalence of SLE shows great variation worldwide. In their 2011 
review Senga et al report annual incidence rates ranging from 0.3 to 8.7 per 100,000 
per year and prevalence ranging from 1.1 to 534.9 per 100,000, with the highest 
incidence occurring in USA, Caribbean, Brazil and Sweden.SLE is generally less 
common in Europe and Asia 
A. In Europe, Caspard et al reported an epidemiological 
study for England from 1998 to 2010, noting an annual incidence of 5.5 per 100000 
per year 
B
. In a US study analysing 34,339 SLE patients with Medicaid coverage, 
Feldman et al reported an incidence of 23.2 per 100,000 per year and a prevalence 
of 144 per 100,000. This study found an unusually high prevalence and incidence 
that is likely to reflect the nature of the inclusion criteria (i.e. limited to Medicaid 
users) and is discussed later in this review in the context of the influence of social 
deprivation  .In contrast two state-based studies, the Georgia Lupus Registry 
72
 and 
the Michigan Lupus Epidemiology and Surveillance Program 
127
, identified potential 
cases from a wider range of sources, albeit over narrower geographical areas. The 
overall age-adjusted incidence rate was 5.6 per 100,000 per year for the Georgia 
Lupus Registry and 5.5 per 100,000 per year for the Michigan study, with an age-
adjusted prevalence rate of 73 per 10, 000 reported for both studies. These studies 
all confirm that black race/ethnicity is associated with higher incidence and 
prevalence with this difference being most marked in women (see below). 
2. Influence of gender 
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SLE predominantly affects females of childbearing age, with only 4-22% patients 
being male. Feldman et al. study found that SLE prevalence was over six times higher 
in women (192/100,000 for women vs 32/100,000 for men) 
28
.  The Georgia Lupus 
Registry reported age-adjusted prevalence of 128/100,000 for women vs 15/10, 000 
for men, and the Michigan Lupus Epidemiology and Surveillance Program reported 
129/100,000 for women and 13/100,000 for men 
72,123
.  As alluded to earlier, the 
highest risk group in all these studies are black women, with a prevalence of 
286/100,000 in the Feldman study, 196/100 000 in the Georgia study, and 
186/100,000 in the Michigan study. 
 
The extent to which there is a distinct male lupus syndrome remains controversial. 
Some have reported a higher disease activity at presentation 
96
, with others 
suggesting that men with SLE have a more aggressive course 
133
, but a careful review 
of the literature by Murphy and Isenberg et al. determined that these studies often 
lack correction for confounders such as ethnicity or age and that overall there is 
limited data available for a negative prognostic association between male gender 
and disease activity or mortality. They do however agree that differences in system 
involvement between the sexes may be seen, with men being less likely to be 
affected by musculoskeletal symptoms, photosensitivity, oral ulcers and RP {Au: 
what is “RP”} than women 
97,59
.  
 
3. Influence of age 
Late onset SLE (>50 years) appears to run a milder course compared to childhood 
onset SLE 
C
 (<18 years).  Simmons et al analyzed the influence of ethnicity and 
gender changes according to age of onset, with the female bias increasing across age 
groups 
C
. Late onset SLE is particularly associated with the clinical features of 
pulmonary involvement and serositis. It is also more commonly associated with 
positive rheumatoid factor and ANA, but the significance of this is unclear since 
these serological markers are also more common in the non-SLE elderly population. 
Even though late onset SLE is associated with poorer survival, this is likely to be due 
to the interaction of inflammation and ageing increasing atherosclerosis 
6
. In 
contrast to the milder course of late onset SLE, childhood onset SLE is aggressive 
with a higher prevalence of renal and neurological involvement and irreversible 
damage 
D
. Anti-RNP positivity, anti-Sm positivity and a low CH50 (50% haemolytic 
complement) are more common in early than late onset SLE 
6
.   
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4. Influence of social deprivation 
In addition to the established influences of ethnicity, gender and age, social 
deprivation appears to be a risk factor for SLE. In their socio-demographic analysis of 
Medicaid Users in the US, Feldman et al. found significant differences according to 
socioeconomic status with the highest prevalence in the lowest socioeconomic 
status quartile (prevalence of 168/100,000), a difference that persisted even 
adjusting for age, sex and race/ethnicity. They comment that the Medicaid group 
are a ‘high-poverty group, with significant racial and ethnic minority representation.’ 
It is likely that these two factors account for the higher incidence and prevalence 
seen in this cohort compared to most previous US studies
 28 
.  
 
5. Socioeconomic burden 
SLE can have a substantial effect on the quality of life of the affected individuals. The 
2013 Lupus European Online (LEO) survey which was completed by 2,070 European 
patients, detected that nearly 70% of patients felt the disease had affected their 
careers, with 27.7% changing careers within one year of diagnosis. The main 
complaint was reduced productivity as a result of fatigue (82.5%), with decreased 
ability to plan affecting all areas of daily life 
42
. This decrease in productivity can lead 
to employment loss within 3.7 years from diagnosis in up to 57% of patients and is 
associated with older age at diagnosis, black race, and less education 
73
. 
Taking all the above into account, physicians need to be aware of the serious 
implications that SLE has in health care planning, resource allocation and service 
provision. 
6. Mortality 
Even though survival has improved over the past forty years, the mortality rates for 
SLE are around four times higher than that of the general population.  In a detailed 
analysis of a single-center cohort in Canada between 1970 and 2013, Sheane et al. 
found that, in the first five years since diagnosis, the leading causes of death were 
infection (49%) and active SLE (34%), whereas in later years death is most likely to 
be from infection (26%) or atherosclerotic complications (23%), with active SLE only 
being responsible for 15% of deaths 
122
. 
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II. Update on Pathogenesis of SLE 
A. Genetic susceptibility in SLE and insights into its immunopathogenesis 
SLE has a high heritability (>66%) and higher concordance rate in monozygotic 
compared to dizygotic twins. Sibling recurrence risk ratio is 8-29% fold compared to 
the general population. Genome-wide association studies (GWAS) and candidate 
gene studies have been performed in patients with SLE in different ethnic groups. 
The results show some genes are identified as risk factors in all studies regardless of 
the ethnic groups` studies, whereas others are specific to different ethnic 
populations. A recent review based on data from the National Human Genome 
Research Institute’s Catalog of published GWAS and a PubMED search for all large 
scale trans ethnic or multi-ethnic studies identified 89 genes in 74 genomic regions 
associated with SLE 
112
. Many of these genes can be linked into specific pathways to 
inform the pathogenesis of SLE, in association with environmental factors including 
ultraviolet light, smoking and infection. 
A major group of genes identified in these studies (including HLA-DR, HLA-DQ, Blk 
and PTPN22) are all involved in immune cell signaling. HLA-DR and -DQ molecules 
present antigen to T lymphocytes leading to activation and cytokine production. The 
strongest association is HLA—DRB1*0301, a class II Major histocompatability 
complex molecule that presents antigen T lymphocytes. A recent meta-analysis of 
four independent European SLE cohorts supported a significant association of HLA-
DRB1*0301 in different sub-phenotpypes of SLE 
91
. PTPN22 C1858T is a coding 
polymorphism associated with increased risk of SLE. PTPN22 forms a complex with 
Csk, a molecule that inhibits T cell receptor signaling, leading to an increase in 
autoreactive cells in the periphery 
91
. PTPN22 has a functional role in B cells with 
increased expression of Syk and PLC-2, molecules downstream of the B cell 
receptor leading to increased proliferation and resistance to apoptosis. Similarly, Blk 
is a B cell tyrosine receptor that signals downstream of the B cell receptor 
53
. 
A second group of genes, including C1q, C2, C4 FcGR2a, FcGR3a and ITGAM 
(complement receptor 3), are involved in immune complex processing. SLE is a type 
III hypersensitivity response with anti-nuclear antibodies and their autoantigens 
forming complexes that are trapped in capillary vascular beds. Complement is a 
major mechanism involved in the clearance of such immune complexes. Defects in 
complement components, particularly C1q and C4, decreases clearance and lead to 
inflammation. Similarly polymorphisms in Fc-gamma receptors will also affect 
immune complex clearance.   
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A third group of genes identified in these studies (including IRAK-1, IRF5, Trex1, 
TNFAIP3) are related to responses to cellular damage particularly DNA. IRF5 is one of 
the most frequently identified loci outside the MHC region in SLE genetics studies. 
IRF5 regulates expression of interferon-dependent genes and apoptosis. Recognition 
of DNA or single stranded RNA by Toll-like receptors (TLR) 7-9, leads via IRAK1 and 
type 1 interferon, to induction of Trex1. Trex1 is a repair endonuclease that can 
degrade DNA from apoptotic cells. Deficiency in the clearance of damaged DNA 
leads to more interferon production and an inflammatory response. TNFAIP3 
encodes for the Tumor necrosis factor, alpha-induced protein 3 (TNFAIP3 protein; 
also known as A20), that inhibits NF-kB- mediated inflammatory responses induced 
by TLR. Polymorphisms in STAT4 that encodes a signaling molecule downstream of 
type 1 IFN, are also associated with increased risk of SLE.  
Many of the genes associated with SLE are associated with other autoimmune or 
autoinflammatory diseases suggesting common pathways 
57
. TREX1 polymorphisms 
are associated with Aicardi-Goutieres syndrome, characterized by encephalopathy 
and lupus-like symptoms. TREX1 polymorphisms are highly prevalent in Cree Indians 
and Aicardi-Goutieres syndrome was originally described as ‘Cree encephalitis’ in 
this community. The persistence of certain mutations associated with SLE over time 
are based on admixture between Neanderthals and early humans, strongly 
indicating that these mutations have a protective effect against a common 
challenge, but that in combination with many other gene variants become 
deleterious  
99
. 
B.  Type 1 Interferons 
Raised serum levels of type 1 interferons have been reported in patients with SLE. 
Manifestations of SLE that could be linked to raised type 1 IFN include lymphopenia, 
myalgia, muscle weakness, headache other neuropsychiatric problems and fatigue 
101,138
. In addition, as discussed earlier, a number of IFN regulated genes have been 
associated with increased risk of SLE. 
C.   MicroRNAs and their role in immunoregulation 
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MicroRNAs (miRs) are conserved non-coding RNA molecules that bind to messenger 
RNAs to either Inhibit or degrade, controlling cell signaling and other cellular 
processes. A recent analysis identified 27 miRs associated with SLE. Expression of 
miR21 in particular was increased in CD4
+ 
T cells and strongly correlated with disease 
activity. Silencing of miR-21 reversed the activated phenotype of T cells from 
patients with SLE including the ability to induce B cell maturation into plasma cells. A 
potential gene target of miR21 was identified being the known tumor suppressor, 
programmed cell death -4 protein (PCD4). PCD4 was shown to be suppressed by 
miR-21 and its expression was decreased in active SLE 
128
. In the context of 
immunoregulation, this is of interest because decreased PCD4 leads to an increase in 
IL-10, whereas lipopolysaccharide (LPS)-induced upregulation of miR21 inhibits this 
process 
83,123
. Increased IL-10 via reduced PCD4 by increased miR21 would lead to 
increased activity in B cells and more autoantibody production. In patients with SLE, 
miR148a and miR126 are raised in CD4
+ 
T cells and target DNA methyltransferase-1 
that is involved in methylation of genes during proliferation of cells. miR146a 
mediates the type 1 IFN pathway suppressing IRAK1 and IRF5 and its expression is 
inversely correlated with disease activity in patients with SLE. Many other miRs have 
been found in SLE, and their function will be of interest in future studies. 
D. Other recent insights into the pathogenesis of SLE 
The central role of the B cell in the pathogenesis of SLE is further supported by the 
clinical data from the novel therapeutic agent belimumab. Belimumab is a 
monoclonal antibody that targets TNF ligand superfamily 13B (also known as B cell 
activating factor [BAFF]). BAFF and a related cytokine TNF ligand superfamily 13 
(also known as a proliferation-inducing ligand [APRIL]) are essential for the 
maturation and survival of immature B cells. Serum concentrations of both BAFF and 
APRIL are raised in patients with SLE. In murine studies animals induced to 
overexpress BAFF have high numbers of mature B cells and autoantibodies and 
develop a disease similar to SLE in humans 
138
. Successful human trials of belimumab 
that causes inhibition of BAFF provides further evidence of the importance of this 
pathway in the disease process. 
On activation, neutrophils release a fibrous net composed of DNA, proteins and 
small peptides from inside the cell. These structures are known as neutrophil 
extracellular traps (NETs) and the process as ‘NETosis’. It is suggested that the 
primary role of NETs is to trap bacteria and fungi leading to their destruction. 
NETosis is a normal process, but, in patients with SLE, antibodies such as anti-RNP 
and anti-HNP can induce NETosis on binding to Fcreceptors on the neutrophil 
surface. Moreover reduced clearance of antibodies leads to cell damage and 
chromatin released from damaged cells can induce IFN production from 
neutrophils which can exacerbate disease 
74,110,149
. 
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Epstein-Barr virus (EBV) has been linked to the development of SLE with patients 
showing a high viral titer, up 40% higher than healthy controls, in blood cells. 
Moreover EBV DNA is found in serum from 42% of SLE patients, compared to 3% of 
controls. EBV lytic replication may be linked to onset of SLE and to flares. This could 
link to pregnancy where inhibition of immune responses leads to release of control 
of EBV and SLE relapse 
26
. Meta-analysis of twenty-five case controlled studies 
supported the link between EBV and SLE 
47
.  
Although there is increasing knowledge of the pathways and molecules involved in 
SLE, there have hitherto been no clear biomarkers for diagnosis or prognosis of the 
disease. Recent studies are beginning to identify such biomarkers, at least for some 
manifestations of SLE. In one study, a 48-plex antibody array was used to identify 
biomarkers in patients with SLE nephritis. The results showed a decrease in C1q, and 
increased interleukin-6 and low density lipoprotein in initial studies 
106
 .In another 
study, serum levels of vascular cell adhesion molecule-1 (VCAM-1) and E-selectin 
were analysed in female patients with lupus compared to healthy individuals. E-
selectin levels were raised in patients and correlated with overall tissue damage and 
carotid plaque, while VCAM-1 levels were associated with active renal disease 
126
.   
 
III. Update on the Diagnosis of SLE 
A. Current diagnostic criteria  
Until recently, the diagnostic criteria for SLE were based on the 1997 update of the 
1982 American College of Rheumatology (ACR) Criteria for Classification of SLE. They 
covered 11 domains of disease manifestations and associations 
Table 1
 with at least 
four of the eleven criteria needed to be present for diagnosis 
52
. 
 
1.Malar Rash          
Fixed erythema, flat or raised, over the malar eminences,  tending to spare the nasolabial folds                                                          
2.Discoid Rash  
Erythematous raised patches with adherent keratotic scaling and follicular plugging; atrophic scarring 
may occur in older lesions 
3.Photosensitivity  
Skin rash as a result of unusual reaction to sunlight, by patient history or observed by physician 
4.Oral Ulcers  
Oral or nasopharyngeal ulceration, usual painless, observed by physician 
5.Nonerosive Arthritis  
Involving two or more peripheral joints, characterized by tenderness, swelling or effusion 
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6.Pleuritis or Pericarditis  
A. Pleuritis- convincing history of pleuritic pain or rubbing heard by physician or evidence of pleural 
effusion 
OR 
B. Pericarditis- documented by electrocardiogram or rub or evidence of pericardial effusion 
7.Renal Disorder  
A. Persistent proteinuria > 0.5 gram per day or > 3+ if quantitation not performed 
OR 
B. Cellular casts- may be red cell, hemoglobin, granular, tubular or mixed 
8.Neurologic Disorder  
A. Seizures- in the absence of offending drugs or known metabolic derangements; e.g. uremia, 
ketoacidosis, or electrolyte imbalance 
OR 
B. Psychosis- in the absence of offending drugs or known metabolic derangements; e.g. uremia, 
ketoacidosis, or electrolyte imbalance 
9.Haemotologic Disorder  
A. Haemolytic anemia- with reticulocytosis 
OR 
B. Leukopenia- <4000/mm3 on > 2 occasions 
OR  
C. Lymphopenia-<1500/mm3 on >2 occasions 
OR 
D. Thrombocytopenia-<100000/mm3 in the absence of offending drugs 
10.Immunologic Disorder  
A. Anti-DNA: antibody to native DNA in abnormal titer 
OR 
B. Anti-Sm: presence of antibody to Sm nuclear antigen 
OR 
C. Positive finding of antiphospholipid antibodies on: 
- an abnormal serum level of IgG or IgM anticardiolipin antibodies 
-a positive test result for lupus anticoagulant using a standard method or 
-a false positive test result for at least 6 months confirmed by Treponema pallidum immobilization or 
fluorescent treponemal antibody absorption test 
11.Positive ANA  
An abnormal titer of antinuclear antibody by immunofluorescence or an equivalent assay at any point 
in time and in the absence of drugs 
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Table 1. American College of Rheumatology (ACR) criteria  
As concerns developed about the clinical criteria used in the ACR classification and 
the lack of validation, the SLE International Collaborating Clinics (SLICC) group 
formed. In 2012 they revised and validated the ACR criteria to include new 
knowledge and improve clinical relevance. A new classification system was produced 
comprising 11 clinical and 6 immunological criteria 
Table 2
.  For a diagnosis of SLE at 
least 4 criteria, including at least one clinical and one immunologic criterion, must be 
satisfied or the patient must have biopsy proven lupus nephritis in the presence of 
antinuclear antibodies or anti-double stranded DNA antibodies 
108
. 
  
Clinical Criteria 
1.Acute cutaneous lupus, including: 
Malar rash 
Bullous lupus 
Toxic epidermal necrolysis variant  
Maculopapular lupus rash 
Photosensitive lupus rash 
In the absence of dermatomyositis 
OR subacute cutaneous lupus 
2.Chronic cutaneous lupus, including: 
Classic discoid rash 
Hypertrophic lupus 
Lupus panniculitis 
Mucosal lupus 
Lupus erythematosus tumidus 
Chillblains lupus 
Discoid lupus/Lichen planus overlap 
3.Oral ulcers  
Palate (buccal, tongue) 
OR nasal ulcers 
In the absence of other causes 
4.Non-scarring alopecia  
In the absence of other causes 
5.Synovitis  
Including >2 joints, characterized by swelling or effusion 
OR tenderness in >2 joints and  
at least 30min morning stiffness 
6.Serositis  
Typical pleurisy for more than 1 day 
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      OR pleural effusions 
      OR pleural rub 
Typical pericardial pain 
      OR pericardial effusion 
      OR pericardial rub 
      OR pericarditis by       electrocardiography 
7.Renal  
Urine protein-to-creatinine ratio representing 500mg protein/24hrs 
OR 
Red blood cell casts 
8.Neurologic 
Seizures 
Psychosis 
Mononeuritis multiplex 
In the absence of other causes 
Myelitis 
Peripheral or cranial neuropathy 
Acute confusional state 
In the absence of other causes 
9.Haemolytic anaemia   
10.Leukopenia (<4000/mm3 at least once)  In the absence of other 
causes 
OR Lymphopenia (<1000/mm3 at least once) In the absence of other 
causes 
11.Thrombocytopenia (<100000/mm3 at least once) 
Immunologic Criteria 
1.ANA level 
Above laboratory reference range 
2.Anti ds DNA antibody level  
Above laboratory reference range 
3.Anti-Sm  
Presence of antibody to Sm nuclear antigen 
4. Antiphospholipid antibody positivity as determined by any of the 
following:  
Positive test result for lupus anticoagulant  
False-positive test result for rapid plasma reagin 
Medium or high titer anticardiolipin antibody level 
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Positive test result for anti-b2-glycoprotein 1 
5.Low complement  
Low C3 
Low C4 
Low CH50 
6.Direct Coombs test  
In the absence of haemolytic anemia 
   Table 2. SLICC Criteria 
 
B. Update on key systemic features seen in SLE 
As a multi-organ disease SLE can affect the kidneys, skin, mucous membranes, joints, 
CNS, lungs, heart, gut, and hematological system to variable degrees. 
1. Renal 
Renal involvement is one of the commonest and most serious manifestations of SLE 
affecting between 20-60% of the patients 
E 
with a higher prevalence in non-whites 
F
. 
Lupus nephritis is not only an indicator of disease severity but is also identified as a 
clinical predictor of flare ups 
58
 . It ranges from mild, `background` glomerulo-
nephritis to chronic kidney disease (CKD), with 10-30% progressing to end stage CKD 
within 15 years. Renal biopsy in these patients is of crucial importance, since the 
histopathologic findings guide the choice of treatment 
19
. 
 
2. Musculoskeletal 
Arthritis in SLE is common and can affect any joint with a particular predilection for 
the hands and knees. Surrounding tissues can be also involved with tendonitis, 
tendosynovitis, tendon ruptures 
44
 and avascular necrosis of larger joints 
(osteonecrosis) as well as osteoporosis secondary to steroid use 
17
. 
 
3. Mucocutaneous 
The skin can be involved in up to 85% of SLE and the involvement variable from 
disease specific malar rash, discoid rash, photosensitivity, oropharyngeal ulcers, 
alopecia, lupus panniculitis and lichen planus  to SLE non-specific manifestations like  
Raynaud`s phenomenon, atrophiae blanche, bullous lesions, livedo reticularis, 
cutaneous vasculitis, and periungual teleangiectasias 
136  
. 
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4. Neurologic 
In 1999 the American College of Rheumatology produced case definitions for 19 
neuropsychiatric syndromes seen in SLE, in an attempt to standardise nomenclature. 
The syndromes that can affect the central or peripheral nervous system 
1
 are listed 
below 
Table 3
. Headaches, cognitive dysfunction, mood disturbances and seizures are 
commonest in childhood SLE 
105
. 
 
Central Nervous System Involvement in SLE Peripheral Nervous System Involvement in 
SLE 
1. Aseptic Meningitis 
2. Cerebrovascular Disease 
3. Demyelinating Syndrome 
4. Headache 
5. Movement Disorder 
6. Myelopathy 
7. Seizure Disorder 
8. Acute Confusional State 
9. Anxiety Disorder 
10. Cognitive Dysfunction 
11. Mood Disorder 
12. Psychosis 
1.Acute Inflammatory Demyelinating 
Polyradiculoneuropathy 
2.Autonomic Disorder 
3.Mononeuropathy 
4.Myasthenia Gravis 
5.Cranial Neuropathy 
6.Plexopathy 
7.Polyneuropathy 
 
              Table 3. Neurologic syndromes in SLE 
 
5. Pleuro-Pulmonary 
It has proven difficult to confirm the true prevalence of pulmonary involvement in 
SLE because of high rates of pulmonary infections in this group. The overall 
involvement is to the result of pleuritis, parenchymal changes, pulmonary vascular 
disease, diaphragmatic dysfunction and upper airway obstruction. A large UK series 
of 216 patients confirmed that 25% of SLE patients had lung involvement diagnosed 
clinically and/or on imaging, whereas autopsy findings confirmed up to 97% of 
pleuro-pulmonary involvement, with pleuritis the commonest (77.8%), followed by 
bacterial infections (57.8%) and alveolar hemorrhages (25.6%) 
64
. 
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6. Cardiac 
The commonest cardiac manifestations of lupus are pericarditis (symptomatic in 
25% of cases, and silent, autopsy-proven in up to 83%), valvular involvement 
confirmed by echocardiogram (up to 60%), coronary artery disease with accelerated 
atherosclerosis and up to 50 fold higher rate of myocardial infarction in female SLE 
patients and pulmonary hypertension (up to 10%). Myocarditis and endocarditis are 
rarer manifestations 
61
. 
 
7. Gastrointestinal 
Gastrointestinal (GI) symptoms are common in lupus occurring in up to 50% of 
patients. They tend to be mild, ranging from dysphagia, dyspepsia, abdominal pain 
to diarrhea 
27
. Most GI manifestations are due to adverse drug reactions and 
infection. True lupus-related GI involvement is rarer but is potentially life 
threatening. Of particular importance is lupus mesenteric vasculitis (prevalence 0.2-
9.7% in SLE), manifesting as acute ischemic enteritis or chronic multiple ulcers of the 
colon, protein-losing enteropathy (prevalence 1.9-3.2%), intestinal pseudo-
obstruction and acute pancreatitis. These complications occur during active lupus, 
and may be a presenting feature of the disease. They tend to respond well to early 
diagnosis and treatment 
135
. 
 
8. Haematologic 
The hematological manifestations of SLE include anemia, leucopenia, 
thrombocytopenia and anti-phospholipid syndrome. The prevalence of hematologic 
disturbances and severity are variable and range from 20% 
129
 to 82% 
121
.  Up to 10% 
of patients can develop a severe hematologic crisis, due to hemolytic anemia or 
severe thrombocytopenia and this seems to be associated with more significant 
disease in the kidneys and CNS. It has been argued that hematological changes may 
be a common initial presenting feature of SLE but because of low index of suspicion 
or inadequate follow up, the diagnosis missed 
121,129
.   
 
C. Update of the key ophthalmic features seen in SLE  
 
Lupus can affect any part of the eye and visual system with significant impact on 
vision despite earlier recognition and improved treatment modalities. Ocular 
manifestations affect around one third of patients with SLE and may be the 
presenting feature of the disease 
23,125
. Ocular manifestations are important both in 
their own right, but also because worsening ocular disease may indicate underlying 
systemic disease activity 
103
. Within the search criteria of this article (2011-2014), 
there have been few recent studies which provide information on the ophthalmic 
features of SLE and their current prevalence in the context of improving systemic 
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disease control. For the reader’s benefit, we present the following summary that 
includes these newer studies but places them within the context of the previous 
data on ophthalmic features in SLE. Some of this data depends on original studies 
prior to 2011 and/or reviews. Further details are available in a number of reviews 
including those of Sivaraj et al 
125
 and Palejwala et al. 
103.
.  
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1. Cornea and Ocular Surface 
Keratoconjunctivitis sicca or secondary Sjogren syndrome affects around 30% of 
patients and is the commonest ocular manifestation of SLE. Symptoms range from 
mild to severe, associated with a spectrum of disease encompassing corneal 
epitheliopathy, scarring, ulceration and filamentary keratitis 
103
.  Other corneal 
associations of SLE include recurrent corneal erosion syndrome and the potentially 
sight-threatening peripheral ulcerative keratitis, which is indicative of active disease 
125
. Interestingly, a study on the biomechanical properties of the cornea in patients 
with SLE found that they have reduced corneal hysteresis and corneal resistance 
factor, both of which are associated with lower intraocular pressure readings by 
applanation 
145
.  
2. Sclera and Uvea 
Scleral involvement is rare in SLE, with scleritis or episcleritis only reported in 2.4% 
cases 
124
. Episcleritis is generally mild and self-resolving, but the presence of scleritis 
is indicative of active systemic disease. Isolated anterior uveitis is rare, but may 
occur in the presence of scleritis and posterior inflammation 
125
. 
3. Retina 
Lupus retinopathy occurs in around 10% of patients, although the prevalence 
appears to be decreasing in line with better systemic management of these patients. 
Lupus retinopathy tends to be bilateral, but may be asymmetric. It presents with 
retinal hemorrhages, cotton-wool-spots, arteriolar narrowing with capillary dilation 
and venous dilation and tortuosity (Fig 1), as well as retinal edema, exudates and 
microaneurysms. It is considered to be an immune-complex vasculopathy rather 
than a true inflammatory vasculitis with fibrinoid degeneration and necrosis of the 
vessel wall 
148
.  
Mild retinopathy may be asymptomatic and an incidental finding, whereas severe 
vaso-occlusive retinopathy presents with reduced vision, distortions, and visual field 
defects. Up to 72% of eyes can progress to neovascularization (Fig 2), with sequelae 
such as vitreous hemorrhage (63%), retinal traction and detachment (27%). 
Manifestations include central or branch retinal artery occlusions (Fig 3) and central 
or branch retinal vein occlusions, either combined or in isolation; 63.6% of newly 
diagnosed SLE patients can develop a retinal vein occlusion within four years and 
females under 50 years of age are at higher risk 
148
.  Associated antiphospholipid 
syndrome has previously been reported to increase the risk of both ocular and CNS 
vaso-occlusion by up to four times, 
7
Additionally, a similar retinopathy with 
occlusion of major retinal vessel may be seen in primary antiphospholipid syndrome, 
and this diagnosis ought to be considered where there is a consistent ophthalmic 
picture, but an absence of typical systemic features of SLE 
8
. 
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Other rarer retinal manifestations of lupus include a retinitis pigmentosa (RP)-like 
retinopathy (‘pseudo RP retinopathy’), choroidopathy with serous retinal 
detachments and frosted-branch angiitis-like vasculopathy 
23,50
. 
4. Neuro-ophthalmic 
Neuro-ophthalmic manifestations are rare and can present as unilateral or bilateral 
ischemic optic neuropathies (anterior and/or posterior) or with an optic neuritis that 
may resemble that seen in demyelinating optic neuritis 
125
. Optic nerve involvement 
may be the presenting feature of SLE 
32
. 
Oculomotor abnormalities may be seen, with sixth nerve palsies being the 
commonest 
103
.  Other rarer manifestations include internuclear ophthalmolplegia, 
nystagmus, pupillary abnormalities, light-near dissociation, blepharospasm, 
transient monocular visual loss, field defects, and cortical blindness 
125
. 
5. Orbit 
The orbit and periorbita are very rarely involved in SLE. Findings can include itching, 
madarosis, pain, edema, proptosis, enophthalmos, decreased vision, chemosis and 
extra-ocular muscle limitation of movement.  These can be due to periorbital edema 
(incidence 4.8%), vasculitis, myositis and panniculitis. Orbital vasculitis is the most 
devastating as it may lead to visual loss. Orbital myositis may be initially 
misdiagnosed as bacterial cellulitis 
103
 and orbital panniculitis is often, but not 
always, associated with discoid lupus of the skin and can resolve spontaneously 
without cicatricial lid changes 
45
. 
Trochleitis is a rare manifestation of orbital lupus, but may be the presentation of 
the disease. A recent case report describes sequential bilateral trochleitis as the 
presenting feature of SLE 
30
. 
6. Intraocular infections 
Because of their immunosuppressed state, lupus patients are more prone to 
developing infections, with nearly half developing a serious infection during the 
course of the disease 
G
. Intraocular infections are rare, but potentially sight-
threatening, including cytomegalovirus retinitis 
67
, acute retinal necrosis (from 
herpes simplex and varizella zoster viruses), tuberculous choroidal abscesses, and 
nocardia endophthalmitis 
23
. 
 
  7. Other drug induced ophthalmic complications 
The most common ophthalmic side-effects of treatment are related to the use of 
corticosteroids and include corticosteroid-induced lens opacity (typically posterior 
subcapsular) and corticosteroid –induced ocular hypertension or glaucoma 
115
. 
Additionally, the less common complication of corticosteroid-induced central serous 
chorioretinopathy may arise, leading to challenging therapeutic decisions as it may 
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be difficult to differentiate this from an SLE-induced choroidopathy 
68
. 
Hydroxychloroquine and chloroquine may induce a sight-threatening retinopathy 
which is discussed later in this article. 
A summary of common and uncommon ophthalmic manifestations of SLE is given 
below 
Table 4
. 
 
Ophthalmic Manifestation                   Common                                                    Uncommon     
Cornea                                                     Keratoconjunctivitis sicca                      Recurrent Erosion        
                                                                                                                                       Syndrome                        
                                                                                                                                       Peripheral Ulcerative 
                                                                                                                                       Keratitis 
Sclera                                                                                                                            Scleritis/Episleritis 
Uvea                                                                                                                              Uveitis 
Retina                                                     Mild Retinopathy                                    Severe retinopathy    
                                                                                                                                   (neovascularization/ 
                                                               Retinal Artery/Vein Occlusion                vitreous haemmorhage) 
                                                                                                                                    Pseudo-RP like       
                                                                                                                                    retinopathy 
                                                                                                                                    Choroidopathy with  
                                                                                                                                     Serous detachments    
                                                                                                                                     Frosted branch angi- 
                                                                                                                                     itis like vasculopathy 
                                                                                                                                      
Neuro-ophthalmic                            6
th
 nerve palsies                                          Ischemic Optic Neuropathy 
                                                                                                                                    ischemic Optic Neuritis 
                                                                                                                                     Internuclear Ophthalmo- 
                                                                                                                                     plegia 
                                                                                                                                     Pupil abnormalities 
                                                                                                                                     Blepharospasm 
                                                                                                                                     Transient monocular 
blindness 
Orbit                                                                                                                            Vasculitis 
                                                                                                                                      Myositis 
                                                                                                                                      Panniculitis    
                                                                                                                                      Trochleitis 
Infection                                                                                                                      Retinal Necrosis  
                                                                                                                                      CMV retinopathy 
                                                                                                                                      Tuberculous Choroidal   
                                                                                                                                      Abscesses 
                                                                                                                                     Nocardia endophthalmitis 
Table 4. Common and uncommon ophthalmic manifestations of SLE 
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D. The diagnostic challenge of incomplete lupus 
Lupus is characterized by heterogeneous clinical and immunological features, 
making the development of highly sensitive and specific classification criteria 
difficult. Current diagnostic criteria (ACR and SLICC), designed for the purposes of 
research study rather that clinical use, require four out of a relatively limited 
selection of clinical and immunological features 
52,108
 . It is widely recognized that 
lupus can also present with additional clinical manifestations that are not 
incorporated into these formal diagnostic criteria. The BILAG scoring system, that is 
used to quantify disease activity rather than act as a diagnostic system, recognizes a 
wide range of non-diagnostic features that can be part of lupus 
48
.  
Clinically patients are often encountered who do not fulfill strict criteria for lupus. 
They may have a relatively mild phenotype with less than four diagnostic features or 
they may have disease (possibly aggressive disease) that particularly targets an 
organ that is not part of the diagnostic classification scheme. Ophthalmic and 
hepatic involvement in lupus are good examples of the latter. 
Patients with milder disease that does not meet full criteria are often termed as 
having ‘incomplete lupus erythematosus’ or ‘undifferentiated connective tissue 
disease’ (UCTD). This is different from ‘mixed connective tissue disease’ that is an 
entity characterized by hard clinical features that truly overlap between defined 
connective tissue diseases (for example lupus and systemic sclerosis), often 
accompanied by anti- RNP antibodies 
102
. Up to 50% of patients with connective 
tissue disease would fall into an UCTD category at disease onset 
2
. Patients seen in 
clinic with UCTD features will therefore fall into three groups, those with ‘stable 
UCTD’, those with spontaneously remitting UCTD symptoms and those likely to 
progress to a definite CTD over a reasonable short period of time. It has been 
proposed that the term stable UCTD could apply to patients with a positive ANA, at 
least one CTD feature, and a disease duration of greater than three years 
93
. Up to 
two-thirds of UCTD patients fall into this category 
14,143
. These patients are 
predominantly women who remain stable over time and rarely develop life- or 
organ-threatening disease 
95
. The commonest clinical features are Raynaud 
phenomenon and arthralgias, but these patients’ perceived quality of life is poor 
45,46,131 
. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
For those patients in whom UCTD will evolve into a defined connective tissue 
disease, this will usually happen earlier in the disease course with systemic lupus 
erythematosus and primary Sjogren syndrome being the most common CTDs to 
develop. Identifying which patients will evolve is an important challenge to address.  
In general the presence of evolving autoantibody specificities, including antibodies 
to dsDNA, which have been observed to accrue prior to the onset of lupus, suggest 
the development of overt disease is likely 
5,49,141
. A prominent interferon-induced 
gene signature and altered Th17/Treg ratios have been proposed as immunological 
markers of progression from incomplete lupus to systemic lupus erythematosus, but 
our understanding is limited 
71,131
. Although not definitive, there is suggestive 
evidence that hydroxychloroquine can delay or prevent the development of full-
blown lupus in patients presenting with an incomplete picture 
62 
. Potent 
immunosuppression or regular corticosteroids would not generally be used. 
Patients with SLE whose disease predominantly affects a single solid organ out of 
proportion to other disease activity present a different challenge--and again one 
without a clear evidence base for treatment. We do however have a precedent from 
lupus nephritis that is commonly observed to involve kidneys alone. A pragmatic 
approach suggests that severe involvement affecting any other organ (for example 
liver or eye) to the extent that organ function is threatened would warrant 
aggressive management similar to active nephritis. 
IV. Update on the Treatment of SLE 
A. Principles of treatment in SLE including targets, disease     
monitoring and guidelines 
From the perspective of disease survival, the prognosis for patients with lupus has 
improved dramatically since the 1950’s 
78
. The vast majority of patients now survive 
the years immediately following their diagnosis, so discussion has moved on to the 
definition of alternative treatment targets in order to objectively improve the 
outcome for patients. Suggested treatment targets have included: optimized control 
of inflammatory disease activity, a reduction in the accrual of permanent organ 
damage, a minimization of glucocorticoid exposure (and hence corticosteroid-
related damage) and a reduction in longer-term mortality. Some have suggested the 
development of formal ‘treat-to target’ guidelines for lupus, analogous to those 
already proposed for rheumatoid arthritis 
92
.  
1. Disease activity indices  
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Given than lupus is such a heterogeneous disease, an important step forward has 
been the development of standardised tools that allow the capture of disease 
activity across multiple systems. A number of tools are in existence (reviewed 
elsewhere X), the most widely used being the Systemic Lupus Erythematosus Disease 
Activity Index (SLEDAI) and British Isles Lupus Assessment Group (BILAG) index 
15, 48
. 
SLEDAI and subsequent derivations generate a global score of disease activity at the 
point of assessment (or within the last 10 or 28 days depending on version used) 
using a weighted system of the commonest and most severe disease manifestations 
in addition to routinely measured immunological parameters (anti-dsDNA antibody 
titres and serum complement levels). The BILAG index captures the widest range of 
clinical disease features. In its updated version (BILAG 2004 index) it explicitly scores 
activity in the last month across nine domains (constitutional, musculoskeletal, 
mucocutaneous, hematological, renal, abdominal, ophthalmic, cardiorespiratory and 
abdominal) and considers whether features are new, getting worse, same or better 
55
. Comparison studies suggest both SLEDAI and BILAG indices may be used for 
capturing disease activity and flare in large cohorts. The BILAG 2004 index, however, 
has the advantage of specifically scoring rare disease manifestations such as 
ophthalmic lupus, with orbital inflammation, severe keratitis, scleritis, posterior 
uveitis, retinal vasculitis, retinal/choroidal vaso-occlusive disease, optic neuritis, and 
anterior ischemic optic neuropathy all counting as category A 
93,146,147
 features(severe 
and indicating that an escalation in treatment is usually required). The widely 
utilized system for recording the accrual of damage in lupus is the SLICC/ACR 
damage index 
39
. Cataracts and retinal ‘change’ or atrophy are ophthalmic features 
that score in this damage index. It is important for the ophthalmologist to appreciate 
the distinction between clinical manifestations indicative of disease activity and 
those resulting from damage. For example sight-threatening corneal perforation 
may occur in the context of severe ocular dryness (damage) but in the absence of 
active inflammation (activity). Disease activity and damage may of course co-exist, 
but the distinction is important to help the clinician direct treatment appropriately. 
2. Treatment guidelines 
The most recent attempt to comprehensively review the management of lupus and 
issue treatment guideline based on expert opinion was published by EULAR in 2008 
11
. A similar review focusing specifically on neuropsychiatric lupus was published in 
2010 
12
. Since these guidelines were published, considerable further evidence has 
been gathered to guide the optimal use of conventional treatment. This has 
particularly been the case in lupus nephritis, where the relative frequency of this 
disease manifestation, the ease of clearly defining disease involvement through 
biopsy, and the potentially catastrophic outcome of patients with active nephritis 
has made this group a focus for research. The accumulated evidence is such that no 
fewer than three nephritis-specific guidelines, KDIGO, EULAR and ACR were 
published in 2012 
13,46,65
. 
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In addition to evidence supporting the use of conventional therapy, there is growing 
evidence to support the use of newer, targeted biological therapies in lupus. In the 
remainder of this review we will consider the recent advances made in the 
management of lupus using conventional and biological agents. 
 
 
B. Conventional immunosuppressants in SLE 
The current mainstay of lupus treatment is conventional immunosuppression using 
hydroxychloroquine, azathioprine, mycophenolate, and cyclophosphamide (and to a 
lesser extent methotrexate and the calcineurin inhibitors), supported by 
glucocorticoids. The precise mechanism of action of most of these drugs remains 
uncertain, and their use in lupus has derived from previous experience in treating 
other inflammatory diseases or from transplantation medicine. Side-effects 
including infection remain a significant limiting factor. Although these drugs have 
been used for some years now, treatment regimens continue to evolve based on 
growing evidence.  
 
1. The role of anti-malarials 
 
Traditionally considered a ‘mild’ lupus treatment and perhaps non-essential for 
many patients, accumulated data suggests multiple beneficial effects from 
hydroxychloroquine (HCQ) that apply to all patients. A recent comprehensive review 
evaluated 95 randomised controlled trials and observational studies of 
hydroxychloroquine in lupus 
120
. Reviewed evidence concluded hydroxychloroquine 
reduced disease activity across the whole spectrum of severity, reduced disease 
activity during pregnancy, and reduced overall mortality. Evidence also supported a 
reduction in lupus-related thrombotic events and accumulated organ damage. 
Similarly anti-malarials (in this case chloroquine [CQ]) may have a role in maintaining 
remission in patients with previously active disease 
90
. It has therefore been 
proposed that “hydroxychloroquine should be given to most patients with SLE 
during the whole course of the disease, irrespective of its severity” 
120
. 
Retinal toxicity remains a concern, with ongoing debate as how best to monitor 
patients taking antimalarials for the treatment of SLE or other rheumatological 
conditions. Although not the primary focus of this review, this is an issue for 
practicing ophthalmologists and rheumatologists, and therefore we provide a brief 
update here. Toxicity due to HCQ remains relatively rare, but appears to be 
increasing in prevalence, with more recent estimates suggesting an incidence of 
around 1% after 5-10 years of use and rising with increased duration of use 
144
.  
In 2011 the American Academy of Ophthalmology (AAO) published an update on 
recommendations for screening for CQ and HCQ toxicity advising that most patients 
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are routinely given 400 mg of HCQ daily “except for individuals of short stature, for 
whom the dose should be determined on the basis of ideal body weight to avoid 
overdosage”. They recommend that patients get a baseline examination within the 
first year of use and annual screening after 5 years of use. In higher risk patients, 
annual screening should not be delayed till 5 years. Screening visits should include 
detailed ophthalmologic examination (visual acuity, corneal examination, dilated 
fundoscopy), automated visual field test of the central 10° (e.g. Humphrey 10-2 test) 
and at least one of spectral domain optical computed tomography, multifocal 
electroretinogram (mfERG), or fluorescein (where available) 
80
.  
In the UK the current guidelines are the 2009 Royal College of Ophthalmologists 
(RCOphth) guidelines developed in collaboration with British Society of 
Rheumatologists and the British Association of Dermatologists which advise a 
maximum dosage of 6.5mg/kg/d based on lean body weight, with baseline and 
annual screening to include establishing the presence or absence of renal and liver 
dysfunction, enquiring about any visual impairment which is not corrected by 
refraction, and recording reading performance with a near vision chart. Referral to 
ophthalmologists should be done if: (1) there is suspected visual impairment at 
baseline which is confirmed by an optometrist, or (2) the patient notices reduced 
vision, patchy central vision or distorted central vision while on treatment. 
Recommendations for examination by ophthalmologists include tests for visual 
acuity and reading, central visual field (Amsler grid or automated perimetry), and 
slit-lamp examination of the cornea and retina. Where there is concern, evaluation 
may also include retinal photography, OCT, FFA and electrophysiologic tests. The UK 
2009 recommendations advise: “it does not believe that the available evidence 
supports the introduction of a programme of systematic screening for 
hydroxychloroquine toxicity at the present time”. Although they state that 
“indefinite follow-up is not likely to be required for most patients”, they do advise 
that individual arrangements may be agreed at the local level as to whether 
ophthalmologists screen patients who have received > 5 years of treatment 
H
. 
In addition to enabling earlier detection of disease, the advent of more sensitive 
measures of retinal structure and function have provided additional evidence of the 
progression of HCQ toxicity after drug cessation 
87
. A number of reports emphasize 
that no one modality can be relied on in isolation as some patients will have 
functional changes (e.g. on automated visual field testing or on mfERG) before 
structural changes or vice versa 
79,81,86
. 
2. The Management of Lupus Nephritis 
 
For the induction of disease remission, all guidelines recognize the benchmark set by 
the original NIH trials (monthly high dose intravenous (IV) cyclophosphamide with IV 
methylprednisolone followed by tapering oral corticosteroids) 
16
. Subsequent 
evidence has clearly delineated two alternatives. Firstly, the ‘Euro-lupus’ 
cyclophosphamide regimen (6 x 500mg IV cyclophosphamide pulses) has been 
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shown to be as effective as high dose cyclophosphamide, at least in patients of 
white European ancestry who do not have rapidly progressive kidney failure 
54
. The 
equivalence of NIH and Euro-Lupus regimens in this group of patients has been 
demonstrated up to 10 years post treatment initiation 
55
. Secondly, mycophenolate 
mofetil (MMF, 2-3g/day) is as effective as cyclophosphamide in inducing remission in 
lupus nephritis 
4
. The equivalence of cyclophosphamide and MMF, but the better 
side-effect profile of MMF has been subsequently confirmed in study meta-analyses 
63,78
. There is some suggestion MMF may be more effective in patients of a non-
white European background, possibly because cyclophosphamide is less effective in 
this group 
59
. 
 
3. The management of non-renal lupus 
 
In contrast to the proliferation of recent trials in lupus nephritis, evidence for the 
optimal prescribing of traditional immunosuppressants in non-renal lupus is lacking. 
This is an area that has recently been reviewed elsewhere, and only trials from 2005 
onwards have been discussed here 
104
. Many of these trials are small, the patients 
are heterogeneous, and the outcome measures are highly variable and often not 
validated in clinical trial research. These factors make it difficult to compare studies 
or draw any firm conclusions. Attempting to standardize lupus trial reporting in the 
light of this has been highlighted 
41
. 
For mild to moderate lupus, double-masked data supported the use of leflunomide 
and, in particular given the size of the study (N=215), methotrexate as a treatment 
and steroid-sparing agent when compared with placebo alone 
31,132
. In an open label 
comparison of azathioprine and cyclosporin, both were equally effective as steroid 
sparing agents and no difference in disease activity or flare was seen between 
groups 
43
. In an analysis of the non-renal outcomes in patients recruited to the 
previously discussed ALMS study of lupus nephritis (high dose IV cyclophosphamide 
vs. MMF) no difference in non-renal disease activity or flare was seen between 
groups 
4,38
 . This evidence that MMF is an effective treatment for non-renal lupus 
supports the findings of an earlier case series of 86 treated patients, and supports 
the conclusions of a previous review of the early mycophenolate literature 
89,111
. An 
unmasked trial treating neuropsychiatric lupus with i.v. methylprednisone and i.v. 
cyclophosphamide vs. i.v. methylprednisolone alone, with oral corticosteroids in 
both groups suggested a better response rate at 24 months for the 
cyclophosphamide group 
9
. An alternative cyclophophamide trial in heterogeneous 
cohort including neuropsychiatric, nephritis and other manifestations concluded 
that the traditional monthly high-dose cyclophosphamide was as effective as an 
even higher dose accelerated 4-day regimen. Complete response was around 50% at 
30 months in both groups 
107
. 
While the evidence is not strong enough to formulate firm guidance, it appears to 
support options such as methotrexate and cyclosporin in patients with mild to 
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moderate disease manifestation, support the use of MMF in patients with more 
severe disease, and support the use of traditional cyclophosphamide regimens in 
patients with neuropsychiatric lupus. There is of course very little specific evidence 
in relation to the treatment of ophthalmic lupus. The methotrexate trial had one 
patient with unspecified ophthalmic disease in each of the case and control arms, 
while the neuropsychatric lupus cyclophosphamide study has one patient with optic 
neuritis in the control arm and three in the treatment arm: in neither study is this 
sufficient to conduct an ophthalmic subgroup analysis 
9,31
. 
 
C. Biological agents in SLE 
 
Conventional treatments by no means provide a cure for lupus and can be 
associated with significant side effects, notably infection because of  non-specific 
immunosuppression. As our understanding of the immunopathogenesis of lupus has 
grown, so has interest in the use and development of biological therapies that 
specifically target components of the immune system that drive disease activity.  
 
1. Belimumab 
 
Belimumab is a human monoclonal antibody that targets and neutralizes soluble B-
lymphocyte stimulator (BLyS – also known as BAFF), a B-cell activating factor that 
induces B-cell proliferation and maintains survival. Efficacy in patients with 
moderately active non-renal lupus was assessed in two masked, randomized, 
placebo-controlled trials (The BLISS-52 and BLISS-76 trials) 
34,100
. Most trial patients 
had musculoskeletal and mucocutaneous disease, and in these domains belimumab 
was shown to reduce disease activity and prevent disease flares. Belimumab was 
approved by the US Food and Drug administration in 2011, but in the UK 
authorization for use within the National Health Service was turned down on the 
basis of a cost vs. benefit decision. Follow-up of initial trial patients for up to seven 
years suggests ongoing efficacy and safety, but data are currently lacking for a role 
in lupus nephritis or more severe non-renal lupus requiring cyclophosphamide 
36
. No 
patients with ocular disease were included in these trials, and for the moment it 
seems unlikely belimumab would have a role to play in managing ophthalmic 
complications of SLE. A trial of dual blockade of BLyS and a second B-cell survival 
factor called APRIL (a proliferation-inducing ligand) using the monoclonal antibody 
atacicept for the treatment of lupus nephritis was terminated early due the rapid 
development of hypogammaglobulinemia and excess infection in patients that were 
also given background MMF  
37
. 
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2. Rituximab 
 
Rituximab is a chimeric anti-CD20 monoclonal antibody. Intravenous infusion leads 
to a rapid depletion of circulating CD20-positive mature B-cells, an effect which 
typically lasts a few months before reconstitution from CD20-negative B-cell 
precursor populations. Following anecdotal reports of efficacy in other autoimmune 
diseases, initial data suggesting efficacy in lupus emerged in 2002 
70
. Large open-
label retrospective case series and prospective registry data suggested, and continue 
to suggest, efficacy in patients with lupus failing conventional therapy 
24,72,113,134
. 
Initial enthusiasm for rituximab was curbed by disappointing results in phase III 
randomized controlled trials in active renal (LUNAR trial) and non-renal (EXPLORER 
trial) lupus 
85,118
. Poor trial design and the maintenance of a high dose of 
corticosteroids across all patients, is likely to have played a role in the failure of 
these trials. Despite these studies the use of rituximab for remission induction in 
lupus nephritis has become standard practice in some centers 
20
. Initial 
observational data suggesting a combination of rituximab and mycophenolate can 
dramatically limit the need for regular background corticosteroids is to be 
investigated further 
20
. Emphasizing our incomplete understanding of the 
immunological sequelae of B-cell depletion strategies is the premature termination 
of a trial of ocrelizumab, a fully humanized anti-CD20 monoclonal antibody, due to 
unacceptable rates of serious infection in the treatment group that were also given 
background MMF 
98
. Ocrelizumab continues to be evaluated in other disease 
settings. 
 
3. Epratuzamab 
 
Epratuzamab is a humanized monoclonal antibody targeting another B-cell antigen, 
CD22. In contrast to rituximab it does not induced marked B-cell depletion, but 
exerts complex immunomodulatory effects 
114
.  The phase II EMBLEM study 
suggested safety and efficacy over a 12-week period 
140
. The underpowered 
ALLEVIATE study also suggested a beneficial effect and had a long (>6month) open 
label extension period with no additional safety concerns 
139
. No patients with 
ophthalmic disease were recruited to these Phase II studies. Phase III studies (the 
EMBODY studies) are in progress. 
 
4. Other biological agents in SLE 
 
A considerable number of potential biological and non-biological therapeutic 
compounds have been investigated in pre-clinical and animal model studies. Some 
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have completed early phase human clinical trials, and these are summarized below 
Table 5
. 
Sifalimumab 109  
Human neutralizing anti-IFNα monoclonal. 
Large study (n=161). Well tolerated. Efficacy trend. 
Trial phase ½. 
Rontalizumab 82 
Humanized neutralizing anti-IFNα monoclonal. 
Well tolerated. No disease activity data. 
Trial phase 1. 
Sirukinamab 130 
Human anti-IL-6 monoclonal. 
Well tolerated in humans. Murine efficacy data. 
Trial phase 1. 
Paquinimod 
10 
Small molecule innate immunomodulator. 
Well tolerated in humans. Murine efficacy data. 
Trial phase 1. 
Abatacept 
33     
(class III/IV lupus nephritis) 
Ig-CTLA-4 fusion protein. 
Large study (n=298) Well tolerated. Failed to meet primary endpoint. 
Trial Phase 3 
Abatacept 
84  
(non-renal lupus) 
Ig-CTLA-4 fusion protein. 
Well tolerated but primary and secondary endpoints not met. 
Trial Phase 2b 
N-acetylcysteine 
69 
Glutathione precursor. Blocks lymphocyte mTOR. 
Safe. Improvement in disease activity. 
Trial Phase ½.
 
Deoxyspegulin 
75 
Small molecule multi-target immunomodulator. 
Quite high dropout due to side effects. Reduction in proteinuria in lupus nephritis. 
 Trial Phase ½. 
                            Table 5. Other biologic agents in SLE
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An additional novel approach to treatment is through the use of stem cell 
transplantation. There have been a number of reported cases of long lasting disease 
remission in previously active and treatment resistant disease using myeloablation 
followed by immune reconstitution with autologous hematopoietic stem cell 
transplantation 
3
. Although perhaps effective or indeed curative, the potential risks 
of this therapy are likely to preclude routine use for most patients with lupus. An 
alternative approach has been to utilize the potential immunoregulatory effect of 
donor stem cells without prior myeloablation. A recent multicenter study using 
donor umbilical cord mesenchymal stem cell infusions in patients with active lupus 
refractory to conventional immunosuppression, suggested therapeutic benefit, 
although a number of patients relapsed after 6 months implying that repeated 
infusions may be needed 
142
. 
 
D. Anticoagulation 
 
Some patients with systemic lupus erythematosus also have anti-phospholipid 
syndrome, an acquired autoimmune condition leading to vascular thrombosis 
(including potential ophthalmic involvement 
123
) or recurrent pregnancy failure, pre-
eclampsia or placental insufficiency. Current research criteria (the Sydney criteria) 
for defining anti-phospholipid syndrome are outlined below 
Table 6
. At least one 
clinical and one laboratory criteria are required to make the diagnosis 
88
. 
Clinical Criteria 
1. Vascular Thrombosis            >1 Arterial, venous or microvascular thrombosis 
 
2. Pregnancy morbidity          A. >1 foetal death beyond 10
th
 week of gestation 
                                                    B. >3 otherwise unexplained miscarriages before 
                                                       10
th
 week of gestation 
                                                   C. Pre-term delivery of an otherwise normal baby 
                                                      before 34 weeks gestation due to eclampsia, severe 
                                                       pre-eclampsia or placental insufficiency 
 
Laboratory Criteria                  Must be present on 2 occasions 12 weeks apart. 
1. Positive lupus anticoagulant in plasma 
2. Medium or high titer anti-cardiolipin antibodies 
3. Positive anti-β2-glycoprotein I antibodies 
Table 6. The Sydney criteria for the definition of anti-phospholipid syndrome 
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Recent (2012) management guidelines, based on a comprehensive review of 
available literature, have been published, and we would refer the reader to these for 
a comprehensive review of the topic 
66
.  While it is generally accepted that the 
management of primary anti-phospholipid syndrome and of anti-phospholipid 
syndrome in patients with SLE is no different, 
35
. there are a number of controversial 
areas, including whether it is responsible for clinical manifestations that are not 
clearly a consequence of a defined thrombotic process, for example migraine or 
demyelination 
18,56
. Similarly, there is controversy over management. A ‘standard’ 
regimen of anticoagulation (INR 2.5) has been adopted as a grade 1A evidence based 
guideline by some, based on randomized control trial data 
21,29,66
. Others, however, 
have used extensive retrospective review data to propose more aggressive 
anticoagulation (INR 3.5) particularly in those with arterial disease, and this regimen 
also has its supporters 
35,119
. The role of ‘primary prevention’ in patients with positive 
laboratory criteria, but no clear thrombotic history, and the treatment of patients 
with a suggestive clinical picture, but no abnormal laboratory tests (‘sero-negative 
anti-phospholipid syndrome’) is also unclear and beyond the scope of this review.  
 
E. Treatment for Ophthalmic Disease 
 
Our literature search identified no randomized controlled trials specific to the  treatment of 
the ophthalmic manifestations of SLE, although a number of studies include ophthalmic 
manifestations as part of the disease activity index (such as those using BILAG 2004). 
Ophthalmic manifestations of SLE may be a warning that the underlying SLE is inadequately 
controlled and indicate that systemic treatment should be escalated (as described earlier). If 
there is no evidence of systemic inflammation, then some manifestations (notably ocular 
surface and anterior segment disease) may be adequately treated with standard topical 
therapies. Although there is no RCT evidence specific to these manifestations in SLE, general 
guidance would be a dual approach: 1) ensure that systemic control of SLE is optimized and   
2) deliver best practice therapeutics/interventions for any residual features. For example in 
dealing with the common problem of ocular surface disease in patients with SLE, 
international recommendations described in the DEWS report may be used to guide the 
clinician in the careful assessment and hierarchical treatment of the multiple contributory 
factors that may lead to dry eyes 
I
.  
Whilst RCT evidence is lacking, we found a number of recent case reports and case series of 
treatment of ophthalmic complications of SLE. The role of intravenous corticosteroid 
treatment is highlighted by two reports. Hernandez-da Mota et al reported a 16-year-old 
with SLE who, despite treatment with azathioprin and deflazacort, developed a frosted 
branch-like angiitis, which resolved after a three day course of intravenous 
methylprednisolone (500mg) and a tapering regime of oral prednisolone 
50
. Similarly Frigui et 
al reported two patients presenting with bilateral visual loss, diagnosed with a bilateral optic 
neuritis and an ischemic bilateral optic neuropathy respectively. Both patients were 
extensively investigated, and an underlying systemic diagnosis of SLE made. Treatment with 
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intravenous methylprednisolone and tapering oral prednisolone led to a partial, but 
incomplete, recovery of visual function in both cases 
32
. 
There have been a number of case reports of the use of rituximab in ophthalmic 
complications of SLE. In particular SLE retinal vasculitis may respond positively both in adult 
and children: The first report of its use in this context was by Hickman et al who reported a 
33-year-old woman with sequential bilateral severe retinal vasculitis who failed to respond 
to intravenous methylprednisolone alone and developed second eye involvement after 
commencing cyclophosphamide, but subsequently went into remission on rituximab 
51
. Since 
then Damato et al reported a 25- year-old woman who, after acute treatment with plasma 
exchange, went into remission and was maintained on a combination of rituximab, 
mycophenolate mofetil and prednisolone 
22
.  Similarly Donnithorne et al, presented two 
adolescent girls (a 16-year-old f and a 13-year-old) who, after acute treatment with 
intravenous methylprednisolone, were maintained on a combination with rituximab, 
cyclophosphamide, and oral corticosteroids 
25
. Rituximab has also been reported to be 
successful in the treatment of SLE-associated orbital pseudotumor that had been refractory 
to corticosteroids and cyclophosphamide 
40
. 
Conclusion 
SLE is a life-threatening multisystem condition that is commonly associated with ocular 
pathology, either directly attributable to the disease or to the treatments employed. We 
have reviewed recent advances in our understanding of the pathogenesis, diagnosi,s and 
treatment of SLE relevant to the ophthalmic community. Improvements in our 
understanding of the genetic and environmental influences on the pathogenesis of SLE is 
informing the development of targeted therapies that it is hoped will control the disease 
more effectively with improved side-effect profiles. Although the diagnosis of SLE may be 
supported by testing for immunological parameters, itremains primarily clinical and thus 
practicing ophthalmologists should be aware of the range of manifestations of SLE. 
Assessment for treatment ought to be decided in conjunction with a lupus specialist, with 
the ophthalmologist leading on the use of topical therapy and advocating systemic 
escalation where the severity of the ophthalmic complications warranted it. A multi-
disciplinary approach is essential for the optimal management of patients with SLE. 
V. Literature search 
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Since this review was an update of the recent literature, a date restriction of 01 Jan 2011 
onwards was used, with the searches being conducted on 01 April 2014. The following 
databases were searched: Medline, EMBASE, Cochrane. The search terms were: SLE, lupus, 
diagnostic criteria, systemic manifestations, ocular manifestations, genetics, epidemiology, 
quality of life, treatment, management. 
Additional articles prior to this date were included where they were deemed by the authors 
to be of ongoing high importance (such as major guidelines that are still active) and/or 
critical to the understanding of the review (such as the ACR diagnostic criteria). 
 
Captions to Images 
Fig 1: Acute Retinopathy in Systemic Lupus Erythematosus with cotton-wool-spots, retinal 
haemmorhages, arterial narrowing and tortuosity. 
Fig 2: Fundus Fluorescein Angiogram depicting vascular leakage due to neovascularization. 
Fig 3: Branch retinal artery occlusion in Systemic Lupus Erythematosus. 
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